Symptoms:
Fatigue, early satiety, shortness of breath, and progressive abdominal fullness; MPN-SAF TSS: 58 (severe)1-3
For US Healthcare Professionals Only
This profile represents a hypothetical patient.
63-year-old1 retired grandfather
Fatigue, early satiety, shortness of breath, and progressive abdominal fullness; MPN-SAF TSS: 58 (severe)1-3
Palpable spleen (9 cm below LCM)1,4,5
Hb: 8.6 g/dL, not transfusion dependent1,4,5
When patients like Roland have anemia with Hb between 8 g/dL and 10 g/dL,
remember to consider common MF treatment goals: spleen volume reduction, symptom improvement, and long-term outcomes1,4-7
Hb=hemoglobin; JAK=Janus kinase; LCM=left costal margin; MF=myelofibrosis; MPN-SAF=Myeloproliferative Neoplasm Symptom Assessment Form; OS=overall survival; SVR=spleen volume reduction; TSS=Total Symptom Score.
References: 1. Verstovsek S, Mesa RA, Gotlib J, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med. 2012;366(9):799-807. Supplemental appendix available at: https://www.nejm.org/doi/full/10.1056/nejmoa1110557. 2. Emanuel RM, Dueck AC, Geyer HL, et al. Myeloproliferative neoplasm (MPN) symptom assessment form total symptom score: prospective international assessment of an abbreviated symptom burden scoring system among patients with MPNs. J Clin Oncol. 2012;30(33):4098-4103. 3. Mitra D, Kaye JA, Piecoro LT, et al. Symptom burden and splenomegaly in patients with myelofibrosis in the United States: a retrospective medical record review. Cancer Med. 2013;2(6):889-898. 4. Data on file. Incyte Corporation. Wilmington, DE. 5. Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010;115(9):1703-1708. 6. Barraco D, Elala YC, Lasho TL, et al. Molecular correlates of anemia in primary myelofibrosis: a significant and independent association with U2AF1 mutations. Blood Cancer J. 2016;6(5):e416. doi:10.1038/bcj.2016.24. 7. JAKAFI/JAKAFI XR Prescribing Information. Wilmington, DE: Incyte Corporation.
JAKAFI®/JAKAFI XR™ (ruxolitinib) is for treatment of intermediate or high‑risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF in adults.
JAKAFI/JAKAFI XR is for treatment of polycythemia vera (PV) in adults who have had an inadequate response to or are intolerant of hydroxyurea.
JAKAFI/JAKAFI XR is for treatment of steroid‑refractory acute graft‑versus‑host disease (aGVHD) in adult and pediatric patients 12 years and older.
JAKAFI/JAKAFI XR is for treatment of chronic graft‑versus‑host disease (cGVHD) after failure of one or two lines of systemic therapy in adult and pediatric patients 12 years and older.
Please see Full Prescribing Information for JAKAFI/JAKAFI XR.